LumiraDx Limited
LMDXW
NASDAQ Global Market0.00
USD
- -
- -
CIK
0001685428
ISIN
KYG5709L1178
CUSIP
G5709L117
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-99.53
76.60
5Y
-99.63
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Veronique Ameye EMBA,
- Full Time Employees
- 1,210
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 3 More London Riverside London United Kingdom SE1 2AQ
- IPO Date
- Sep 29, 2021
- CIK
- 0001685428
- Website
- lumiradx.com
- Similar Companies
- Business
- LumiraDx Limited (LMDXW) develops and commercializes next-generation point-of-care diagnostic platforms and tests that deliver lab-comparable performance using microfluidic technology from a fingerstick or nasal swab sample. The company offers a broad menu of assays including CRP, D-Dimer, INR, NT-proBNP, HbA1c, SARS-CoV-2 antigen, SARS-CoV-2 & Flu A/B, and SARS-CoV-2 & RSV tests, alongside a pipeline for infectious diseases, cardiovascular conditions, diabetes, and coagulation disorders; it also provides connected software solutions such as INRstar for anticoagulation management and DataWell for data sharing. Founded in 2014 and headquartered in London, United Kingdom, LumiraDx operates globally through direct sales and distributors in regions including the US, Europe, Japan, South Africa, Colombia, and Brazil, targeting primary care, urgent care, pharmacies, schools, and decentralized healthcare settings. In July 2024, Roche completed its acquisition of LumiraDx's Point of Care technology platform, related R&D, and operational sites for up to $350 million as part of a pre-packaged UK administration process, with the acquired entities fully integrated into Roche Diagnostics to expand decentralized testing worldwide. LumiraDx Limited entered liquidation proceedings, with its core diagnostic assets now advancing under Roche, including ongoing collaboration with the Bill & Melinda Gates Foundation on molecular tuberculosis testing.